Hills Bank & Trust Co Sells 855 Shares of Illumina, Inc. (NASDAQ:ILMN)

Hills Bank & Trust Co trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 16.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 4,313 shares of the life sciences company’s stock after selling 855 shares during the period. Hills Bank & Trust Co’s holdings in Illumina were worth $601,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. abrdn plc lifted its holdings in Illumina by 764.9% during the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock worth $47,206,000 after acquiring an additional 299,827 shares during the period. J.P. Morgan Private Wealth Advisors LLC bought a new position in Illumina during the third quarter valued at about $29,558,000. International Assets Investment Management LLC increased its holdings in Illumina by 210.5% during the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock worth $6,711,000 after buying an additional 32,672 shares during the last quarter. Aquila Investment Management LLC raised its position in Illumina by 150.0% in the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock worth $3,481,000 after acquiring an additional 15,000 shares during the period. Finally, Weil Company Inc. boosted its stake in Illumina by 59.2% in the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock valued at $3,152,000 after acquiring an additional 8,539 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.17% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ILMN has been the topic of several research analyst reports. StockNews.com downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. OTR Global reiterated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Barclays upped their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. Finally, Scotiabank reduced their price objective on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $164.65.

Illumina Price Performance

NASDAQ:ILMN traded up $0.73 during mid-day trading on Thursday, reaching $111.35. The stock had a trading volume of 1,755,039 shares, compared to its average volume of 1,740,209. Illumina, Inc. has a one year low of $89.00 and a one year high of $213.91. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. The firm has a 50 day moving average price of $128.53 and a two-hundred day moving average price of $126.83. The stock has a market capitalization of $17.74 billion, a P/E ratio of -13.66 and a beta of 1.20.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The firm’s revenue was down 1.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 EPS. As a group, analysts expect that Illumina, Inc. will post 0.91 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.